SIRT1 targeting in CML LSCs, both by inhibition or knock-down, enhances acetylation of P53 which gives rise to apoptosis and reduction of their growth [42]. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.